论文部分内容阅读
目的探讨对老年急性心肌梗死患者实施重组葡激酶静脉溶栓治疗的临床价值。方法选取老年急性心肌梗死患者53例,随即分为两组。其中,对照组26例,给予重组组织型纤溶酶原激活物静脉溶栓治疗;观察组27例,给予重组葡激酶静脉溶栓治疗。对两组患者的治疗效果及并发症情况进行比较。结果观察组患者血管再通情况明显优于对照组,并发出血情况明显低于对照组,两组比较差异具有统计学意义(P<0.05)。结论重组葡激酶用于治疗老年急性心肌梗死安全可靠,效果明显,值得临床推广。
Objective To investigate the clinical value of intravenous thrombolysis with recombinant staphylokinase in elderly patients with acute myocardial infarction. Methods 53 elderly patients with acute myocardial infarction were selected and then divided into two groups. Among them, 26 cases in the control group received intravenous thrombolytic therapy of recombinant tissue plasminogen activator; 27 cases in the observation group received intravenous thrombolysis with recombinant staphylokinase. The two groups of patients with treatment and complications were compared. Results The vascular recanalization in the observation group was significantly better than that in the control group. The bleeding in the observation group was significantly lower than that in the control group. There was significant difference between the two groups (P <0.05). Conclusion Recombinant staphylokinase for the treatment of elderly patients with acute myocardial infarction is safe and effective, the effect is obvious, worthy of clinical promotion.